Revenue $72.0 million in Q1 2024 $65.1 million in Q1 2023 Profit $8.1 million in Q1 2024$1.6 million in Q1 2023 EBITDA, a Non-IFRS measure $28.7 million in.
Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends.